KRAS and non-small cell lung carcinoma: Recently, two drugs that specifically target KRAS G12C, sotorasib (LumakrasTM) and adagrasib (KrazatiTM), have received accelerated approval by the FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy [17, 18].